Eli Lilly's retatrutide achieves 30% body weight reduction in a Phase III trial, approaching bariatric surgery results without an operation.
Eli Lilly has published Phase III results showing that retatrutide, a novel triple-hormone receptor agonist, produces an average 30.1% reduction in body weight, approaching outcomes typically achieved only through bariatric surgery. The results, published in The New England Journal of Medicine, represent the most potent anti-obesity pharmacotherapy ever documented in a randomized controlled trial.
Retatrutide simultaneously activates receptors for three gut hormones: GLP-1, GIP, and glucagon. While existing medications like semaglutide (Wegovy) and tirzepatide (Zepbound) target one or two of these receptors, the triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and fat metabolism.
The TRIUMPH-3 trial enrolled 2,400 adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity across 180 sites in 15 countries. Participants receiving the highest dose of retatrutide lost an average of 30.1% of their body weight over 72 weeks, compared to 3.2% in the placebo group.
Beyond weight loss, the trial demonstrated remarkable improvements in metabolic health markers. Among participants with type 2 diabetes, 82% achieved normal blood sugar levels (HbA1c below 5.7%), effectively representing diabetes remission. Systolic blood pressure dropped by an average of 14 mmHg. Liver fat content, as measured by MRI, decreased by 83%, offering potential benefits for the growing epidemic of metabolic-associated steatotic liver disease.
The safety profile was generally consistent with the GLP-1 receptor agonist class. Gastrointestinal side effects, including nausea and diarrhea, were the most common adverse events but were predominantly mild and tended to diminish over time. The rate of treatment discontinuation due to side effects was 8%, comparable to other medications in the class.
Dr. Ania Jastreboff of Yale University, who presented the results, described retatrutide as a transformative advance in obesity medicine. Obesity affects over 1 billion people worldwide and is a major risk factor for heart disease, diabetes, cancer, and premature death. Despite its prevalence, obesity has historically been undertreated due to limited therapeutic options.
Eli Lilly plans to submit retatrutide for FDA approval in early 2026. If approved, it would join a rapidly expanding market for anti-obesity medications that is projected to reach $100 billion annually by 2030. Access and affordability remain significant concerns, as many insurers still do not cover weight-loss medications.